Table 1

Baseline characteristics of EMmY participants randomised to myo-inositol versus placebo

Baseline characteristicsIntervention (myo-inositol)
N=99, n (%) or mean (SD)
Control (placebo)
N=99, N (%) or mean (SD)
Demography
 Age (years)31.4 (5.8)31.9 (5.6)
 Gestational age at recruitment (weeks)12.4 (1.3)12.3 (1.5)
 BMI (kg/m2)28.2 (6.4)27.9 (5.6)
 Higher education73 (73.7)76 (76.8)
Ethnicity
 White25 (25.3)40 (40.4)
 Asian49 (49.5)48 (48.5)
 Black16 (16.2)8 (8.1)
 Mixed/others9 (9.1)3 (3)
Risk factors for GDM
 GDM in previous pregnancy8 (8.1)11 (11.1)
 Obesity (BMI ≥30 kg/m2)37 (37.4)36 (36.4)
 Minority ethnic origin72 (72.7)59 (59.6)
 Polycystic ovary syndrome9 (9.1)11 (11.1)
 Previous macrosomic baby (>4.5 kg)4 (4)2 (2)
 Family history of diabetes (first degree)60 (60.6)59 (59.6)
Current pregnancy
 Parity0.8 (1)0.9 (0.9)
 Nulliparous50 (50.5)40 (40.4)
 Alcohol use1 (1)0 (0)
 Tobacco use1 (1)3 (3)
 Current use of supplements85 (85.9)89 (89.9)
 Current use of medication24 (24.2)18 (18.2)
 Aspirin8 (8.1)7 (7.1)
General clinical history
 Pre-existing medical condition*4 (4)4 (4)
 Family history of raised lipids (first degree)7 (7.1)8 (8.1)
  • *Pre-existing medical conditions include autoimmune disease, blood/clotting disorder, cardiac problems, liver disease, lung disease, chronic hypertension and renal disease.

  • BMI, body mass index; GDM, gestational diabetes mellitus.